Breaking News Instant updates and real-time market news.

MRK

Merck

$62.68

-0.26 (-0.41%)

14:50
07/19/18
07/19
14:50
07/19/18
14:50

Merck commits to not increase average net prices by more than inflation annually

Merck noted that in 2017, the company issued its second annual Pricing Action Transparency Report, which showed that net prices across Merck's U.S. product portfolio declined by 1.9%. "We believe that further changes are still necessary to help reduce patient out-of-pocket costs. To demonstrate our commitment to achieving this goal, we are making the following announcement: We commit to not increase the average net price across our portfolio of products by more than inflation annually; We are also lowering our price on ZEPATIER by 60% and several other medicines by 10% to reduce out-of-pocket costs for patients across the country. The Merck products selected were based on a range of factors including the gap between list price and actual discounted, or net, prices paid in the market, the contractual obligations under existing arrangements with payers, and the opportunity to broaden access to treatment. Going forward, we will continue to evaluate our portfolio of products to look for opportunities to further reduce costs for patients and the health care system," the company announced.

  • 27

    Jul

  • 10

    Sep

  • 23

    Oct

  • 16

    Feb

MRK Merck
$62.68

-0.26 (-0.41%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

BIIB

Biogen

$230.70

1.49 (0.65%)

16:24
05/20/19
05/20
16:24
05/20/19
16:24
Initiation
Biogen initiated  »

Biogen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SWI

SolarWinds

$19.16

0.04 (0.21%)

16:23
05/20/19
05/20
16:23
05/20/19
16:23
Syndicate
SolarWinds files to sell 17.25M shares of common stock »

JPMorgan, Goldman Sachs,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

AMGN

Amgen

$168.36

-1.5 (-0.88%)

16:21
05/20/19
05/20
16:21
05/20/19
16:21
Initiation
Amgen initiated  »

Amgen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 31

    May

GM

General Motors

$36.98

-0.02 (-0.05%)

16:21
05/20/19
05/20
16:21
05/20/19
16:21
Periodicals
GM plans wind-down of Maven car-sharing service in some cities, WSJ says »

According to the Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 04

    Jun

  • 05

    Jun

  • 01

    Aug

DBVT

DBV Technologies

$8.98

-0.21 (-2.29%)

, AIMT

Aimmune

$19.68

-0.41 (-2.04%)

16:20
05/20/19
05/20
16:20
05/20/19
16:20
Initiation
DBV Technologies, Aimmune initiated  »

Aimmune assumed with an…

DBVT

DBV Technologies

$8.98

-0.21 (-2.29%)

AIMT

Aimmune

$19.68

-0.41 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 13

    Sep

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/20/19
05/20
16:20
05/20/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVNA

Carvana

$67.17

-0.935 (-1.37%)

16:19
05/20/19
05/20
16:19
05/20/19
16:19
Syndicate
Carvana files to sell 3.5M shares of Class A common stock »

Wells Fargo Securities,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

INCY

Incyte

$76.83

-0.41 (-0.53%)

16:19
05/20/19
05/20
16:19
05/20/19
16:19
Initiation
Incyte initiated  »

Incyte initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 24

    May

  • 31

    May

  • 05

    Jun

  • 13

    Jun

GOOG

Alphabet

$1,138.33

-23.56 (-2.03%)

, GOOGL

Alphabet Class A

$1,145.28

-23 (-1.97%)

16:19
05/20/19
05/20
16:19
05/20/19
16:19
On The Fly
Fly Intel: Wall Street's top stories for Monday »

Stocks have started the…

GOOG

Alphabet

$1,138.33

-23.56 (-2.03%)

GOOGL

Alphabet Class A

$1,145.28

-23 (-1.97%)

INTC

Intel

$43.58

-1.3 (-2.90%)

QCOM

Qualcomm

$76.61

-4.91 (-6.02%)

XLNX

Xilinx

$101.05

-3.71 (-3.54%)

AVGO

Broadcom

$272.59

-17.27 (-5.96%)

S

Sprint

$7.34

1.165 (18.87%)

TMUS

T-Mobile

$78.32

2.93 (3.89%)

F

Ford

$10.28

-0.01 (-0.10%)

FB

Facebook

$182.71

-2.56 (-1.38%)

QGEN

Qiagen

$38.05

0.96 (2.59%)

MDCO

The Medicines Co.

$34.25

1.24 (3.76%)

DISH

Dish

$33.24

-2.095 (-5.93%)

SATS

EchoStar

$41.97

1.55 (3.83%)

PDD

Pinduoduo

$20.78

-1.91 (-8.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 20

    May

  • 22

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 24

    Jul

  • 25

    Jul

  • 31

    Jul

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

GH

Guardant Health

$78.29

2.13 (2.80%)

16:18
05/20/19
05/20
16:18
05/20/19
16:18
Syndicate
Guardant Health files to sell 4.5M shares of common stock »

JPMorgan and BofA/Merrill…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 05

    Jun

  • 12

    Jun

  • 18

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/20/19
05/20
16:17
05/20/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSM

Insmed

$28.08

-1.08 (-3.70%)

16:16
05/20/19
05/20
16:16
05/20/19
16:16
Syndicate
Insmed files to sell $250M of common stock »

Morgan Stanley & Co.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/20/19
05/20
16:16
05/20/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEO

NeoGenomics

$23.19

0.22 (0.96%)

16:15
05/20/19
05/20
16:15
05/20/19
16:15
Syndicate
Breaking Syndicate news story on NeoGenomics »

NeoGenomics files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Nov

BKNG

Booking Holdings

$1,751.62

-35.11 (-1.97%)

16:15
05/20/19
05/20
16:15
05/20/19
16:15
Initiation
Booking Holdings initiated  »

Booking Holdings assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TRIP

TripAdvisor

$45.01

0.01 (0.02%)

16:13
05/20/19
05/20
16:13
05/20/19
16:13
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 11

    Jun

EXPE

Expedia

$116.48

0.22 (0.19%)

16:13
05/20/19
05/20
16:13
05/20/19
16:13
Initiation
Expedia initiated  »

Expedia assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

MGM

MGM Resorts

$25.34

-0.54 (-2.09%)

16:11
05/20/19
05/20
16:11
05/20/19
16:11
Conference/Events
MGM Resorts participates in a conference call with UBS »

Leisure, Gaming &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

KR

Kroger

$24.06

-0.165 (-0.68%)

16:10
05/20/19
05/20
16:10
05/20/19
16:10
Upgrade
Kroger rating change  »

Kroger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CLVS

Clovis

$16.35

-0.68 (-3.99%)

16:08
05/20/19
05/20
16:08
05/20/19
16:08
Hot Stocks
Clovis says Rubraca increased symptom-free period in ovarian cancer patients »

Clovis Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 06

    Jun

VRSK

Verisk Analytics

$141.45

-0.56 (-0.39%)

16:07
05/20/19
05/20
16:07
05/20/19
16:07
Conference/Events
Verisk Analytics management to meet with Cantor Fitzgerald »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 05

    Jun

MRVL

Marvell

$21.73

-0.885 (-3.91%)

16:06
05/20/19
05/20
16:06
05/20/19
16:06
Hot Stocks
Marvell to acquire Avera Semiconductor for $650M in cash »

Marvell announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

VNE

Veoneer

$18.84

-0.03 (-0.16%)

16:06
05/20/19
05/20
16:06
05/20/19
16:06
Syndicate
Breaking Syndicate news story on Veoneer »

Veoneer files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

OCUL

Ocular Therapeutix

$3.35

-0.11 (-3.18%)

16:06
05/20/19
05/20
16:06
05/20/19
16:06
Hot Stocks
Ocular Therapeutix says OTX-TP failed to meet primary endpoint in Phase 3 trial »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 10

    Nov

CBAY

CymaBay

$12.37

-0.24 (-1.90%)

16:05
05/20/19
05/20
16:05
05/20/19
16:05
Hot Stocks
CymaBay announces results related to seladelpar clinical development program »

CymaBay Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.